Human Growth Hormone.
Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland.
Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. Human Growth Hormone is fda-approved, and PepCue grades its published evidence S tier (90/100). Also known as HGH · somatropin. This is a research reference, not medical or dosing advice.
What it is
Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.
How it works
GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.
Mechanism pathways
Downstream growth signalling through the IGF-1 receptor and its splice variants.
Insulin-like growth factor 1 is the main mediator of growth hormone's anabolic effects. Growth hormone binds its own receptor on hepatocytes, which dimerises and signals through the JAK2 and STAT5 pathway to drive IGF-1 transcription. Circulating IGF-1 then binds the IGF-1 receptor, a receptor tyrosine kinase closely related to the insulin receptor, which activates the PI3K, Akt, and mTOR cascade alongside the Ras and MAPK cascade. The result is increased protein synthesis, cell proliferation, and suppression of programmed cell death. Muscle also produces IGF-1 locally in response to mechanical loading, and this local supply is thought to matter more for tissue repair than the circulating pool does. A critical regulatory layer is the family of six IGF-binding proteins. The great majority of circulating IGF-1 is bound to these proteins rather than free, which limits how much reaches receptors at any moment and prevents excessive signalling. Several compounds in this group are engineered specifically to evade that control, using amino-acid substitutions and terminal extensions that drop binding-protein affinity dramatically. The consequence is a much larger free fraction and a far longer functional presence than native IGF-1, which is the intended effect and also the source of the main concern about them. A separate branch involves splice variants. Mechanical stress shifts IGF-1 splicing to produce a variant with a distinct carboxy-terminal E-domain, and the isolated E-peptide has been proposed to act on muscle satellite cells through a receptor different from the classical IGF-1 receptor, expanding the stem cell pool before mature IGF-1 drives differentiation. Attaching polyethylene glycol to this peptide is a stability modification rather than a change in mechanism. The honest position differs sharply between branches. Growth hormone and IGF-1 receptor biology is textbook physiology, well established in humans, and recombinant growth hormone is an approved medicine for defined deficiency states. The splice-variant branch is far weaker: independent laboratories have not consistently reproduced the proposed proliferative effect of the isolated E-peptide, and there are essentially no controlled human trials of it. Across the whole pathway, unregulated amplification of a proliferative growth signal raises theoretical concerns about promoting the growth of existing abnormal cells, and these compounds other than approved growth hormone have no established human safety record.
The evidence
The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.
The evidence, in brief
Recombinant hGH (somatropin) is an FDA-approved biologic identical to pituitary GH, with a large body of controlled-trial evidence for growth-hormone deficiency (pediatric and adult) and conditions such as Turner and Noonan syndromes. Unlike the research analogues, it has a defined approval and safety profile.
- Norditropin (somatropin): FDA prescribing informationFDA / DailyMed
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #030
Approved or strong, consistent human evidence.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about Human Growth Hormone, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Recombinant somatropin is approved and supported by randomized trials and systematic reviews in pediatric and adult GH deficiency.
A systematic review in healthy older adults found only small body-composition changes with more adverse events, and advised against anti-aging use.
Performance benefit in healthy or athletic populations is not supported by robust controlled outcome data.
Body-composition shifts are documented, but in healthy adults the magnitude is small and comes alongside more adverse events.
Documented effects include fluid retention, joint pain, carpal tunnel syndrome and impaired glucose tolerance.
Safety profile
Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.
Compound notes
- Human growth hormone (recombinant somatropin) is the actual hormone, not a secretagogue; it acts directly and raises IGF-1.
- It is FDA-approved for specific conditions such as diagnosed GH deficiency and certain growth/wasting disorders.
- Anti-aging, bodybuilding, and general “performance” use is off-label and not proven beneficial for healthy adults.
- Carries real risks (e.g. insulin resistance, edema, joint pain, and concerns around growth signaling); use is medically supervised for approved indications.
- Non-prescription/illicit sourcing adds purity and dosing risk.
Regulatory status
Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.
Approved by the FDA for at least one indication.
By the numbers
- 01A 191-amino-acid pituitary polypeptide; the recombinant drug form is called somatropin
- 02Acts largely through IGF-1 via the GHR/JAK2/STAT5 pathway, but directly opposes insulin to raise glucose
- 03FDA-approved for diagnosed GH deficiency and several specific growth/wasting disorders, not for anti-aging or athletic use
- 04Healthy-elderly trials (Liu 2007) showed small body-composition changes but more adverse events; not recommended as anti-aging therapy
- 05Common adverse effects include edema, joint pain, carpal tunnel syndrome, and insulin resistance/diabetes
- 06Banned by WADA; US law restricts distribution to FDA-approved indications
Human Growth Hormone: research formats
Choose the format you are researching to see route-specific notes.
Approved only when prescribed for specific GH deficiency diagnoses; compounded HGH is illegal.
FDA-approved somatropin (Norditropin, Genotropin, Humatrope, others) is sold as lyophilized powder in vials or prefilled cartridges, typically at 4 IU/mg potency. Reconstituted with the supplied diluent. Only the approved branded products are legal in the US; compounded or imported HGH is not approved.
Sources
Every factual claim above resolves to a real, published source.
- Effects of human growth hormone in men over 60 years old (Rudman)N Engl J Med, 1990, PMID 2355952
- Systematic review: the safety and efficacy of growth hormone in the healthy elderly (Liu et al.)Ann Intern Med, 2007, PMID 17227934
- Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 TrialJ Clin Endocrinol Metab, 2020, PMID 32022863
- Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluationHealth Technol Assess, 2010, PMID 20849734
Cite this page
PepCue. “Human Growth Hormone: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/human-growth-hormone.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.